Microbix Biosystems Inc. develops and commercializes proprietary biological products for human health and wellbeing. Our products, notably native pathogens, are used in immunoassays or as control material in quality assessment and proficiency testing products. Our annual revenues of over $12 million are largely derived from these product lines, referred to as the Antigen or Virology Business.
We have recently expanded our line of control materials to include REDx Controls (TM) line for regular run controls for molecular diagnostics tests, and our PROCEEDx(TM) line for research use only applications including verification and validation panels for new instrument installations. These are in addition to our highly successful PTDx(TM) line which started in 2008 as proficiency test products (referred to as EQA in the EU). Since 2008, we have provided well over 500,000 QAPs samples to proficiency programs, QA and QC departments in research facilities and clinical labs on a global basis.
The company also applies its biological expertise to develop other innovative and proprietary technologies and products. Its development project pipeline currently includes two such proprietary products: (1) Kinlytic® Urokinase, a biologic thrombolytic drug used to treat blood clots, and (2) LumiSort™, a technology for ultra-rapid and efficient sorting of somatic cells that can be used to enrich cell populations of interest, such as in sexing semen.